ArticleBritish journal of cancer2023

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.

S Piperno-Neumann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.